Protagonist Therapeutics News and Activities
Presence
Protagonist Therapeutics develops peptide-based medicines for blood disorders, inflammatory diseases, and rare conditions. Its products and services include drug discovery and clinical-stage therapies for patients, healthcare providers, and pharmaceutical partners.
Protagonist Therapeutics products and services overview:
- Peptide therapeutics
- Drug discovery
- Clinical development
- Blood disorder therapies
- Inflammation treatments
- Rare disease therapies
Revenue: ~$235 million
Employees: 180
Headquarters: Newark, United States (USA)
Protagonist Therapeutics is one of the...
Protagonist Therapeutics is a company listed under the stock ticker PTGX (US).
Executives
View the org chart displaying its 24 main executives
Most searched biographies at Protagonist Therapeutics
- Dinesh Patel, Director, President and Chief Executive Officer
- Bryan Giraudo, Director
- Lewis Williams, Director
Create your alert
to follow the executive moves at Protagonist Therapeutics.
Biotechnology
Protagonist Therapeutics has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
- NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
Popular contacts in Biotechnology
News
Press releases by Protagonist Therapeutics
- Protagonist Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for PTG-300 in Polycythemia Vera | Protagonist Therapeutics, Inc.
- Protagonist Therapeutics to Participate in the Jefferies Next Generation IBD Therapeutics Virtual Summit 2020 | Protagonist Therapeutics, Inc.
- Protagonist Therapeutics Reports Granting of Inducement Award | Protagonist Therapeutics, Inc.
- Protagonist Therapeutics to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference | Protagonist Therapeutics, Inc.
- Protagonist Therapeutics to Host PTG-300 Opportunity Update Webinar | Protagonist Therapeutics, Inc.
- Protagonist Appoints Sarah O'Dowd to Board of Directors | Protagonist Therapeutics, Inc.
- Protagonist Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update | Protagonist Therapeutics, Inc.
- Hepcidin Mimetic PTG-300 Receives U.S. FDA Orphan Drug Designation for the Treatment of Polycythemia Vera | Protagonist Therapeutics, Inc.
- Press Releases | Protagonist Therapeutics, Inc.
- Protagonist Therapeutics to Participate in the BMO Prescriptions for Success Healthcare Conference | Protagonist Therapeutics, Inc.
- View more press releases Close
Social media about Protagonist Therapeutics
- Protagonist Therapeutics on Wikipedia, Google News & Yahoo Finance
- Protagonist Therapeutics on LinkedIn, X (Twitter) & YouTube
